Literature DB >> 21290238

Cannabinoids: potential targets for bladder dysfunction.

Michael R Ruggieri1.   

Abstract

Cannabinoids are the active chemical components of Cannabis sativa (marijuana). The medical use of cannabis goes back over 5,000 years. Cannabinoids produce a very wide array of central and peripheral effects, some of which may have beneficial clinical applications. The discovery of cannabinoid receptors has spawned great interest within the pharmaceutical industry with the hopes of capitalizing on the beneficial effects of cannabis without the unwanted psychotropic effects on the central and peripheral nervous system. This chapter presents an overview of the pharmacology of cannabinoids and their derivatives. It reviews the current literature on central and peripheral cannabinoid receptors as related to effects on the lower urinary tract and the role of these receptors in normal and abnormal urinary tract function. An objective evaluation of the published results of clinical trials of cannabis extracts for the treatment of bladder dysfunction resulting from multiple sclerosis is also presented. It is clear that cannabinoid receptors are present in the lower urinary tract as well as spinal and higher centers involved in lower urinary tract control. Systemic cannabinoids have effects on the lower urinary tract that may be able to become clinically useful; however, a much greater understanding of the mechanisms of cannabinoid receptors in control of the human lower urinary tract is necessary to facilitate development of novel cannabinoid drugs for treatment of pelvic disorders.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21290238     DOI: 10.1007/978-3-642-16499-6_20

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  9 in total

1.  Role of cannabinoid receptor type 1 in tibial and pudendal neuromodulation of bladder overactivity in cats.

Authors:  Xuewen Jiang; Michelle Yu; Jamie Uy; Thomas W Fuller; Cameron Jones; Bing Shen; Jicheng Wang; James R Roppolo; William C de Groat; Changfeng Tai
Journal:  Am J Physiol Renal Physiol       Date:  2016-12-07

Review 2.  Research Findings on Overactive Bladder.

Authors:  Phani B Patra; Sayani Patra
Journal:  Curr Urol       Date:  2015-05-20

3.  Differential neurodegenerative phenotypes are associated with heterogeneous voiding dysfunction in a coronavirus-induced model of multiple sclerosis.

Authors:  Sanghee Lee; Balachandar Nedumaran; Joseph Hypolite; Brian Caldwell; Michael C Rudolph; Anna P Malykhina
Journal:  Sci Rep       Date:  2019-07-26       Impact factor: 4.379

4.  Cannabis-Based Products in a Neurological Setting: A Clinical and Pharmacokinetic Survey.

Authors:  Susan Mohamed; Giovanna Lopane; Loredana Sabattini; Cinzia Scandellari; Diletta Zardi; Vincenzo Donadio; Giovanni Rizzo; Alessandro Perrone; Alessandra Lugaresi; Manuela Contin
Journal:  Front Neurol       Date:  2022-03-24       Impact factor: 4.003

Review 5.  Endocannabinoids in Bladder Sensory Mechanisms in Health and Diseases.

Authors:  Stewart Christie; Simon Brookes; Vladimir Zagorodnyuk
Journal:  Front Pharmacol       Date:  2021-07-05       Impact factor: 5.810

6.  Pharmacology of the lower urinary tract.

Authors:  Martin Hennenberg; Christian G Stief; Christian Gratzke
Journal:  Indian J Urol       Date:  2014-04

Review 7.  Drug therapy of overactive bladder--what is coming next?

Authors:  Karl-Erik Andersson
Journal:  Korean J Urol       Date:  2015-10-02

Review 8.  Expected Next-Generation Drugs Under Development in Relation to Voiding Symptoms.

Authors:  Kyung Jin Chung; Benjamin I Chung
Journal:  Int Neurourol J       Date:  2017-06-21       Impact factor: 2.835

9.  Different Cannabis sativa Extraction Methods Result in Different Biological Activities against a Colon Cancer Cell Line and Healthy Colon Cells.

Authors:  Jan Rožanc; Petra Kotnik; Marko Milojević; Lidija Gradišnik; Maša Knez Hrnčič; Željko Knez; Uroš Maver
Journal:  Plants (Basel)       Date:  2021-03-17
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.